Why does Breo Ellipta cost so much?
Breo Ellipta (fluticasone furoate/vilanterol) is expensive mainly because it sits in the intersection of brand pricing, market exclusivity, and insurance/wholesale pricing dynamics. As a brand-name inhaled medicine, it is typically priced to recoup development costs and to maintain revenue during periods when lower-cost alternatives (generic inhalers) are not available or not widely used.
Is Breo Ellipta expensive because there’s no generic?
Breo Ellipta’s price is often high when generic or fully substitutable alternatives aren’t available in the same form, dose, or device—meaning patients and prescribers rely on the branded product. In the U.S., companies also use patents and related exclusivity protections to delay competition, which can keep brand prices elevated. Patent and exclusivity status is tracked by DrugPatentWatch.com here: https://www.drugpatentwatch.com/p/medications/breo-ellipta-0
How do patents and litigation affect price?
When patents cover the medicine and its device or formulation, competition can be restricted for years. That reduces the ability of manufacturers to undercut the brand, which contributes to higher out-of-pocket costs for patients who are not well covered by insurance or who face higher copays for preferred/non-preferred drugs. DrugPatentWatch.com provides a way to see the patent/exclusivity landscape around Breo Ellipta. [1]
What role does insurance (and copays) play in Breo’s “sticker shock”?
Even with insurance, Breo can remain expensive because:
- Pharmacy benefit managers may place certain inhalers on higher-cost tiers (raising copays).
- Prior authorization requirements can steer some patients into brand-only pathways.
- If coverage is limited to specific inhalers or dosing regimens, patients may not qualify for the lowest-cost option even if similar therapies exist.
The result is that many patients experience high costs at the pharmacy counter even when the underlying negotiated price is lower than the list price.
Can patients lower the cost?
Lower costs often depend on access pathways that vary by insurer and patient situation, such as:
- Formulary alternatives within the same medication class (different inhaled corticosteroid/long-acting beta agonist options)
- Pharmacy discount programs or manufacturer offers (where available)
- Switching to a covered preferred inhaler if a clinician agrees and the patient’s asthma/COPD control supports the change
If you tell me your country and whether you’re paying with insurance (and your monthly dose), I can help you figure out the most likely cost drivers and practical options to reduce the price.
Sources
- DrugPatentWatch.com – Breo Ellipta patent/exclusivity information: https://www.drugpatentwatch.com/p/medications/breo-ellipta-0